Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Jan 19, 2022 10:38pm
235 Views
Post# 34335932

RE:RE:Woth a second look, anyone new, should see

RE:RE:Woth a second look, anyone new, should seeDon't get excited about the GOBLET poster tomorrow.  The abstract is already available on the ASCO site.  It's a simple introduction to the parameters of the trial.  No safety data, no timeline, nothing.  

But...  shoud we get excited about the recent action on the share price?

Yes, ONC has been pumping the company with a ton of paid for advertisments disguised as "resarch reports" to lure naive investors.  But they do this once or twice per year, so I'm used to it even if it makes them look desparate. 

Yes, ONC has and ATM and all previous increases in trading volume within the past three years can be directly attributed to pumping the stock and selling into the market.  Cannacord and LPC are experts at this deceptive practice, but ONC has to get the millions to pay Coffey from somewhere. 

Could it be different this time??  

Maybe!  Primarily because we are so very close to the end of the Bracelet trial.  ONC is in the perfect position for the announcement of a partnership or buyout.  More so than at anytime in the company's history. 

If we see a few trading days with 4 million plus share traded then I will be disappointed... this is evidence of the ATM pump in action. 

If we see one or two weeks of steady increases in SP and slow rise in volumes the it could very well be the real deal this time.  

Good luck everyone. 

Might be an excellent time to gamble on a few thousand warrants.  But remember, YOU NEED 9.5 WARRANTS TO ACQUIRE ONE  SHARE OF ONC.


<< Previous
Bullboard Posts
Next >>